Agenda 1 Analytical Services Ltd
What makes Agenda1 Different?
Agenda1 is an ISO 9001:2008 certified company providing a wide range of analytical services to companies in Life Science and other industries. Occupying a steadily increasing number of units on the Listerhills Science Park in Bradford the company stands out because of the wide range of techniques it has available, most available to cGMP standards if required. All of the equipment is operated by a team of scientists with extensive experience in the fields of drug, medical device, and pharmaceutical technology development.
Agenda1 was formed in 2006, based around the facilities and team remaining when drug delivery company Nektar Therapeutics UK Ltd closed. Nektar UK gained a world class reputation when commercializing a supercritical fluid based API processing technology, and latterly when developing their own drug products. It is that experiential base that in particular sets Agenda1 aside from other analytical companies.
Since 2006, the team has worked with over 100 different clients in supporting Oral, Transdermal, Topical, and IV dose formulation developments. They have also established an enviable reputation for supporting medical device development, particularly in the field of Hydroxyapatite based bone substitute materials.
The Technical Capabilities
Specialist equipment on site includes: X-Ray Diffraction, X-Ray Fluorescence, ICP-OES (MS also available), dry and suspension particle sizing by laser diffraction, and Nitrogen BET surface area / porosity analysis. In addition Agenda1 have more fundamental characteristic assessment techniques including Thermal Gravimetric Analysis (TGA), Differential Scanning Calorimetry (DSC) and Gravimetric/Dynamic Vapour Sorption (GVS/DVS).
The laboratories also boast a good chromatography capability with TLC, HPLC, GC, HS-GC and GC-MS available.
Raw Material testing
Agenda1 have recently become involved more heavily in raw material testing, and have established a dedicated laboratory for this purpose. In addition to auto-titration and Karl Fisher instruments there are UV/UV VIS and FTIR capabilities and relevant associated equipment. Following a major program of raw material method validation for a large pharmaceutical company, the laboratories, and team, are well positioned to handle a very wide range of work in this area.
A further aspect of the capabilities that set Agenda1 apart is their investment in additional techniques to support formulation development. These include a Solubilisation Enhancement Service (Solent™). This is used for screening poorly soluble drugs to identify license free excipient based formulations to solubilise drug products for early stage clinical trials. Tailored formulation screens are available for IV, Parenteral, Oral, and Transdermal dosing. The team also have salt form and co-crystal systems available to assess the impact on solubility/ stability of alternative physical and salt forms.